McDavid Stilwell
Keine laufenden Positionen mehr
Vermögen: 145 339 $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Mark Stolper | M | 52 | 3 Jahre | |
| Lee Newcomer | M | 71 | 2 Jahre | |
| Jill O'Donnell-Tormey | M | 68 | 2 Jahre | |
| Charles Newton | M | 53 | 2 Jahre | |
| Bryan Mcmichael | M | 46 | 3 Jahre | |
| Theresa M. LaVallee | M | 57 | 3 Jahre | |
| David Scharfstein | M | 63 |
Harvard Business School
| 21 Jahre |
| Michael Ryan | M | - | 1 Jahre | |
| Rosh Dias | M | - | 2 Jahre | |
| Paul Reider | M | 55 | 3 Jahre | |
| Richard L. Hameister | M | - | 3 Jahre | |
| Karen Kotz | F | - | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Thomas P. Lynch | M | 57 | 3 Jahre | |
| Eckard Weber | M | 73 | 14 Jahre | |
| Lota Zoth | F | 64 | 7 Jahre | |
| Wendy Dixon | M | 68 | 6 Jahre | |
| Alex Sloane | M | - |
Harvard Business School
| 10 Jahre |
| Aaron Michel | M | - |
Harvard Business School
| 3 Jahre |
| Vincent R. Anicetti | M | 69 | 7 Jahre | |
| David Endicott | M | 58 | 6 Jahre | |
| Monica Forbes | F | 49 | 4 Jahre | |
| Vladimir Vexler | M | 66 | 10 Jahre | |
| John Pontius | M | 68 |
GTx, Inc.
 GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 13 Jahre |
| Deborah Jorn | F | 66 | 2 Jahre | |
| Joseph Hagan | M | 55 | 6 Jahre | |
| Barrington John Albert Furr | M | 80 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 4 Jahre |
| Mary Szela | F | 60 | 7 Jahre | |
| Michael Carter | M | 86 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
| Jason Shackelford | M | 48 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
| Thomas Cannell | M | 62 | 3 Jahre | |
| V. Lawlis | M | 72 | 7 Jahre | |
| Dan Turner | M | 62 | 7 Jahre | |
| James Dalton | M | 61 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 9 Jahre |
| Robert Karr | M | 75 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 6 Jahre |
| Jeffrey G. Hesselberg | M | 65 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
| Heather Turner | F | 51 | 8 Jahre | |
| Kenneth Robinson | M | 69 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
| Alan C. Mendelson | M | 76 | - | |
| James Healy | M | 58 | 8 Jahre | |
| Joseph Lacob | M | 68 | 8 Jahre | |
| Samuel R. Nussbaum | M | 75 | 3 Jahre | |
| Michael Powell | M | 69 | 8 Jahre | |
| Edis Jamyn | M | - |
Harvard Business School
| 2 Jahre |
| Joel M. Podolny | M | - |
Harvard Business School
| 3 Jahre |
| Jonathan T. Pastor | M | - |
Harvard Business School
| 2 Jahre |
| Yon Sog Choi | M | - |
Harvard Business School
| 2 Jahre |
| Marco Giberti | M | - |
Harvard Business School
| 3 Jahre |
| Allison Checchi | F | - |
Harvard Business School
| 2 Jahre |
| Emily johnson lambert | F | - |
Harvard Business School
| 2 Jahre |
| Lea Bajc | F | - |
Harvard Business School
| 2 Jahre |
| Leslie Feinzaig | F | - |
Harvard Business School
| 2 Jahre |
| Adam Said | M | 40 |
Harvard Business School
| 2 Jahre |
| Jose Valentin Pantangco | M | 52 |
Harvard Business School
| 2 Jahre |
| Vanessa Ann Bartram | F | - |
Harvard Business School
| 2 Jahre |
| Mina Pacheco Nazemi | F | - |
Harvard Business School
| 2 Jahre |
| Marc Herdegen | M | - |
Harvard Business School
| 2 Jahre |
| Sherrese Soares | F | 47 |
Harvard Business School
| 2 Jahre |
| Bobby J. Sheth | M | 45 |
Harvard Business School
| 2 Jahre |
| Stephanie Holden | F | - |
Harvard Business School
| 2 Jahre |
| David Dickason | M | - |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 4 Jahre |
| Morven Groves | F | - |
Harvard Business School
| 2 Jahre |
| Alexis DePree | F | 45 |
Harvard Business School
| 2 Jahre |
| Hector Gil | M | - |
Harvard Business School
| 2 Jahre |
| Aliceson Robinson | M | - |
Harvard Business School
| 2 Jahre |
| Nidhi Chadda | F | - |
Harvard Business School
| 2 Jahre |
| Srdjan Tanjga | M | - |
Harvard Business School
| 2 Jahre |
| David Salanic | M | - |
Harvard Business School
| 2 Jahre |
| Scott Alan Cullerton | M | - |
Harvard Business School
| 2 Jahre |
| Juan Enriquez | M | 64 |
Harvard Business School
| 2 Jahre |
| Christopher M. Busby | M | - |
Harvard Business School
| 2 Jahre |
| Marc André Novakoff | M | 49 |
Harvard Business School
| 2 Jahre |
| Brian Wayne Lemasters | M | - |
Harvard Business School
| 2 Jahre |
| Douglas Simmons | M | - |
Harvard Business School
| 2 Jahre |
| Jason Goins | M | - |
Harvard Business School
| 2 Jahre |
| Craig Stern | M | - |
Harvard Business School
| 2 Jahre |
| David Bordeau | M | - |
Harvard Business School
| 2 Jahre |
| David Matthew Friedman | M | - |
Harvard Business School
| 2 Jahre |
| Eliot E. Kerlin | M | 50 |
Harvard Business School
| 2 Jahre |
| Jill Catherine Raker | F | - |
Harvard Business School
| 2 Jahre |
| Fazeela A. Rashid | F | - |
Harvard Business School
| 2 Jahre |
| Benjamin A. Farkas | M | - |
Harvard Business School
| 3 Jahre |
| Danielle Hootnick | F | - |
Harvard Business School
| 2 Jahre |
| Jeff Swenson | M | 48 |
Harvard Business School
| 2 Jahre |
| John Doran | M | 45 |
Harvard Business School
| 2 Jahre |
| Jeremy A. Lynch | M | - |
Harvard Business School
| 2 Jahre |
| Edward Sobol | M | - |
Harvard Business School
| 2 Jahre |
| Alex Alvarez | M | - |
Harvard Business School
| 2 Jahre |
| Alex Kinnier | M | 48 |
Harvard Business School
| 2 Jahre |
| Nico Iacuzzi | M | - |
Harvard Business School
| 2 Jahre |
| Lee Rand | M | - |
Harvard Business School
| 2 Jahre |
| Laura Grattan | F | 42 |
Harvard Business School
| 2 Jahre |
| Min Zhang | F | 50 |
Harvard Business School
| 2 Jahre |
| So-Youn Song | M | - |
Harvard Business School
| 2 Jahre |
| Dong Hao Yang | M | 52 |
Harvard Business School
| 2 Jahre |
| Alex Popa | M | - |
Harvard Business School
| 2 Jahre |
| Özlem Tekay | F | - |
Harvard Business School
| 4 Jahre |
| Adam Dean Checchi | M | - |
Harvard Business School
| 2 Jahre |
| Samuel Clemens | M | - |
Harvard Business School
| 2 Jahre |
| Lily Surya | F | - |
Harvard Business School
| 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 99 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- McDavid Stilwell
- Persönliches Netzwerk
